Inflammatory breast cancer in Tunisia in the era of multimodality therapy

Labidi, Sana Intidhar; Mrad, Karima; Mézlini, Amel; Ouarda, M. Ayadi; Combes, Jean‐Damien; Abdallah, M. Ben; Romdhane, Khaled Ben; Viens, Patrice; Ayed, Farhat Ben

doi:10.1093/annonc/mdm480

Cited by 38 publications

(63 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were three studies from each of Australia [79, 95, 96], Korea [97, 98] and China [99–101]; two studies from Japan [71, 102]; one study from Tunisia [103] and four international studies [19, 104–106]. Study size ranged from 96 [107] to 24 698 patients [97].…”

Section: Resultsmentioning

confidence: 99%

Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies

et al. 2014

View full text Add to dashboard Cite

The current systematic literature review and meta-analysis extends and confirms the associations of obesity with an unfavourable overall and breast cancer survival in pre and postmenopausal breast cancer, regardless of when BMI is ascertained. Increased risks of mortality in underweight and overweight women and J-shape associations with total mortality were also observed. The recommendation of maintaining a healthy body weight throughout life is important as obesity is a pandemic health concern.

show abstract

Section: Resultsmentioning

confidence: 99%

Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Our study reveals a direct relationship of cancer cells with pathogenic bacteria, suggesting a TLR2-mediated mechanism in bacterial infection-associated human breast cancer metastasis. Since many cancer patients with weaken immune systems appear to be susceptible to bacterial infection and surgical contamination and there are always sporadic serious or light cases of surgical infection in clinic every year[3], [5], [49], our findings pointed importance of antibiotic therapy to treat breast tumor with bacterial infection especially of Staphylococcus aureus, a notable drug-resistant pathogen that easily occur in clinic. In addition, as some bacterial vaccine and adjuvant used in cancer treatment usually contain TLR2 agonist, this study is also relevant to genetic strategy for bacterial vaccine and adjuvant design in cancer immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Bacteria Peptidoglycan Promoted Breast Cancer Cell Invasiveness and Adhesiveness by Targeting Toll-Like Receptor 2 in the Cancer Cells

Xie¹,

Huang²,

Xie³

et al. 2010

PLoS ONE

View full text Add to dashboard Cite

Chronic bacterial infection increased the risk of many solid malignancies and the underlying mechanism is usually ascribed to bacterial-caused inflammation. However, the direct interaction of infectious bacteria with cancer cells has been largely overlooked. We identified that highly metastatic breast cancer MDA-MB-231 cells expressed high level of Toll-like receptor 2 (TLR2) in contrast to poorly metastatic breast cancer cells and homogenous untransformed breast cells. TLR2 in MDA-MB-231 cells were actively triggered by peptidoglycan (PGN) from infectious bacterium Staphylococcus aureus (PGN-SA), resulting in the promoted invasiveness and adhesiveness of the cancer cells in vitro. PGN-SA induced phosphorylation of TAK1 and IκB in the TLR2-NF-κB pathway of the cancer cells and stimulated IL-6 and TGF-β secretion in MDA-MB-231 cells. All these effects were abrogated by TLR2 blockade. Further investigation showed that the NF-κB, STAT3 and Smad3 activities were augmented sequentially in MDA-MB-231 cells after PGN-SA stimulation. Phosphorylation of NF-κBp65 was initially increased and then followed by phosphorylation of STAT3 and Smad3 in the delayed 4 or 6 hours. NF-κB inhibition attenuated STAT3 and Smad3 activities whereas PGN-SA-stimulated cell culture supernatants reversed these inhibitory effects. Our study indicated that TLR2 activation by infectious bacterial PGN played an important role in breast cancer cell invasiveness and illustrated a new link between infectious bacteria and the cancer cells, suggesting the importance of antibiotic therapy to treat cancer with bacterial infection.

show abstract

“…In two phase I studies reported at the 2008 ESMO meeting, axitinib was combined with a variety of chemotherapy regimens including FOLFOX and FOLFIRI in gastrointestinal malignancies and taxane-, capecitabine-, or gemcitabine-based treatments in a variety of solid malignancies. In both studies, the pharmacokinetics were not affected by the addition of chemotherapy and the toxicities were not increased 18,19. More involved studies have also explored axitinib chemotherapy combinations with other new agents including a PDGFR inhibitor CP-868,596 combined with docetaxel and axitinib.…”

Section: Outcomes Achieved In Clinical Developmentmentioning

confidence: 99%

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer

Deshpande¹,

Gettinger²,

Sosa³

2009

View full text Add to dashboard Cite

Introduction: Thyroid cancer is a rare disease with an incidence of around 37,000 cases per year. However, its incidence is rising faster than many other cancers and for men this disease ranks highest overall in the rate of increase (2.4% annual increase) in cancer deaths. As the number of radioactive iodine-resistant thyroid cancers increases, the need for newer treatments has become more important. Axitinib is one of many new small molecule inhibitors of growth factor receptors that have shown promise in the treatment of many cancers. It targets the vascular endothelial growth factor receptors 1, 2 and 3. Aims: The goal of this article is to review the published evidence for the use of axitinib in the treatment of thyroid cancer and define its therapeutic potential. Evidence review: The major evidence of axitinib activity has appeared in meeting report abstracts. One phase II study has been published. This included patients with any histological type of thyroid cancer that was not amenable to treatment with radioactive iodine. Clinical potential: To date, in phase II clinical studies axitinib has demonstrated antitumor activity in advanced refractory thyroid cancer. As a monotherapy it resulted in a 30% response rate with another 38% of patients having stable disease. Axitinib appears to have a good tolerability profile, with hypertension being the most common grade 3 or greater side effect.

show abstract

Inflammatory breast cancer in Tunisia in the era of multimodality therapy

Abstract: Tunisian patients with IBC have particular epidemiologic characteristics, with earlier disease and context of overweight and obesity, but prognostic factors are similar to those reported in the literature. Hormone therapy seems to improve patient outcome.

Cited by 38 publications

References 28 publications

Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies

Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies

Bacteria Peptidoglycan Promoted Breast Cancer Cell Invasiveness and Adhesiveness by Targeting Toll-Like Receptor 2 in the Cancer Cells

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer

Contact Info

Product

Resources

About